Skip to Content

InMed Pharmaceuticals Inc INM

Morningstar Rating
$0.41 −0.01 (1.45%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

INM is trading at a 63% discount.
Price
$0.41
Fair Value
$1.88
Uncertainty
Extreme
1-Star Price
$52.39
5-Star Price
$9.53
Economic Moat
Hfsn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INM is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.42
Day Range
$0.380.42
52-Week Range
$0.292.08
Bid/Ask
$0.34 / $0.44
Market Cap
$2.48 Mil
Volume/Avg
104,535 / 196,259

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.33
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
13

Valuation

Metric
INM
Price/Earnings (Normalized)
Price/Book Value
0.18
Price/Sales
0.33
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
INM
Quick Ratio
5.90
Current Ratio
7.03
Interest Coverage
Quick Ratio
INM

Profitability

Metric
INM
Return on Assets (Normalized)
−43.37%
Return on Equity (Normalized)
−51.01%
Return on Invested Capital (Normalized)
−52.16%
Return on Assets
INM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTmbk$550.4 Bil
VRTX
Vertex Pharmaceuticals IncWwfyvdy$111.8 Bil
REGN
Regeneron Pharmaceuticals IncFkdcvwl$107.9 Bil
MRNA
Moderna IncNbn$36.3 Bil
ARGX
argenx SE ADRWpxk$23.0 Bil
BNTX
BioNTech SE ADRBtjxx$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncQgymftf$19.2 Bil
BMRN
Biomarin Pharmaceutical IncPjyrcf$16.4 Bil
RPRX
Royalty Pharma PLC Class ACtmkrz$13.4 Bil
INCY
Incyte CorpYlyvhkl$13.3 Bil

Sponsor Center